Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

5,554 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Immunogenicity and safety of a SARS-CoV-2 mRNA vaccine (SYS6006) in healthy Chinese participants: A randomized, observer-blinded, placebo-controlled phase 2 clinical trial.
Jin F, Qiu Y, Wu Z, Wang YH, Cai C, Fu L, Jiao W, Wang H, Gao M, Su C, Ma JH, Xu Y, Huang CC, Zhang Q, Ni S, Zhao M, Guo L, Ji L, Yang H, Zhao Y, Li C, Lu X, Su YW, Li Q. Jin F, et al. Among authors: huang cc. Vaccine. 2024 Mar 7;42(7):1561-1570. doi: 10.1016/j.vaccine.2024.01.098. Epub 2024 Feb 15. Vaccine. 2024. PMID: 38365485 Clinical Trial.
Safety and immunogenicity of primary vaccination with a SARS-CoV-2 mRNA vaccine (SYS6006) in Chinese participants aged 18 years or more: Two randomized, observer-blinded, placebo-controlled and dose-escalation phase 1 clinical trials.
Chen GL, Qiu YZ, Wu KQ, Wu Y, Wang YH, Zou YY, Peng CG, Zhao J, Su C, Ma JH, Ni SN, Wang X, Jin TH, Jiang Q, Guo T, Xu Y, Huang CC, Zhang Q, Liu KL, Ji L, Yang HY, Li CL, Su YW, Lu X, Li LJ. Chen GL, et al. Among authors: huang cc. Hum Vaccin Immunother. 2023 Dec 15;19(3):2285089. doi: 10.1080/21645515.2023.2285089. Epub 2023 Dec 18. Hum Vaccin Immunother. 2023. PMID: 38111106 Free PMC article. Clinical Trial.
Safety and immunogenicity of heterologous boosting with a bivalent SARS-CoV-2 mRNA vaccine (XBB.1.5/BQ.1) in Chinese participants aged 18 years or more: A randomised, double-blinded, active-controlled phase 1 trial.
Su YW, Qiu YZ, Wang YH, Xu Y, Huang CC, Zhang Q, Su C, Ma JH, Liu W, Liu Y, Zhao MS, Yang HY, Li CL, Lu X. Su YW, et al. Among authors: huang cc. Vaccine. 2024 Apr 2;42(9):2438-2447. doi: 10.1016/j.vaccine.2024.03.005. Epub 2024 Mar 8. Vaccine. 2024. PMID: 38461050 Clinical Trial.
Clinimetric properties of the "FIND-NEEDS" to screen geriatric conditions.
Chang CM, Lin CY, -Hu FW, Wang YW, Huang CC, Lo YT, Wu CY, Chung YF, Kang CC, Chen YJ, Yang YC, Liu LF, Griffiths MD, Lin DC, Shen MR. Chang CM, et al. Among authors: huang cc. Gerontology. 2024 May 13. doi: 10.1159/000539261. Online ahead of print. Gerontology. 2024. PMID: 38740010
Vascular smooth muscle-specific LRRC8A knockout ameliorates angiotensin II-induced cerebrovascular remodeling by inhibiting the WNK1/FOXO3a/MMP signaling pathway.
Lu FT, Huang CC, Lai WY, Yang GY, Liang ZJ, Zhang ZY, Chokshi T, Guo KM, Tang YB, Chen Y, Yang ZH, Liang SJ, Pang RP, Zhou JG, Guan YY, Lv XF, Ma MM. Lu FT, et al. Among authors: huang cc. Acta Pharmacol Sin. 2024 May 8. doi: 10.1038/s41401-024-01280-1. Online ahead of print. Acta Pharmacol Sin. 2024. PMID: 38719954
Estrogen receptor 1 chromatin profiling in human breast tumors reveals high inter-patient heterogeneity with enrichment of risk SNPs and enhancer activity at most-conserved regions.
Joosten SEP, Gregoricchio S, Stelloo S, Yapıcı E, Huang CF, Yavuz K, Donaldson Collier M, Morova T, Altintaş UB, Kim Y, Canisius S, Moelans CB, van Diest PJ, Korkmaz G, Lack NA, Vermeulen M, Linn SC, Zwart W. Joosten SEP, et al. Genome Res. 2024 May 15;34(4):539-555. doi: 10.1101/gr.278680.123. Genome Res. 2024. PMID: 38719469
5,554 results